Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Registration path for SGN-40, partnered with Genentech, could be through front-line treatment of aggressive NHL.